25 news items
A Look at Pharma ETFs Post Q1 Earnings
BMY
JNJ
LLY
9 May 24
The first-quarter results of the healthcare sector have been unimpressive, with earnings of 78% of the sector participants that have reported so
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
AAL
AAPL
ABBV
29 Apr 24
. On the other hand, healthcare, energy, and materials have reported year-over-year earnings declines.
See Also
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY
25 Apr 24
or settlement and exposure to other litigation and/or regulatory actions or investigations; the impact of any healthcare reform and legislation or regulatory
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
BMY
JNJ
MRK
10 Apr 24
the world's scariest health enemy. It’s no exaggeration to say that the direction they chose, which is to revolutionize the existing healthcare
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
BMY
6 Apr 24
and healthcare systems. At Bristol Myers Squibb, we are committed to advancing our robust pipeline of potential medicines for neurological disorders
zkx9s vm76m4n1
BMY
TSVT
5 Apr 24
daily for 7 days following ABECMA infusion at the REMS-certified healthcare facility for signs or symptoms of CRS and monitor patients for signs
6zr43h6zu8hs82xp3yk1nwbn
BMY
ZLAB
1 Apr 24
or metastatic NSCLC who have received at least one prior systemic therapy in 2022.
In 2023, the Medicines and Healthcare Products Regulatory
mwhpmuvmcz4rugleukrqai0vy 36mkjt6ef7iffm3qp6tfrv2hhkqc48o4e
BMY
25 Mar 24
to inform their healthcare provider of all concomitant products prior to and during CAMZYOS treatment
lnohdii7nauv46984vthwoikh2nu7 72d6yjecxqwar
ABBV
ANIX
BIIB
20 Mar 24
. As these companies integrate their new acquisitions, the healthcare landscape anticipates groundbreaking advancements in treatment options and patient care
a4ebs hwqy1dclf6tbqlv7zgl0tga6puncwscvru
ABBV
ANIX
BIIB
20 Mar 24
. As these companies integrate their new acquisitions, the healthcare landscape anticipates groundbreaking advancements in treatment options and patient care
r59nza6czs6x05g0hfr j3jiz4gicuql
ABBV
ANIX
BIIB
20 Mar 24
. As these companies integrate their new acquisitions, the healthcare landscape anticipates groundbreaking advancements in treatment options and patient care
p9th631esu20ubgbno8rckqebqf8gt
BMY
20 Mar 24
at the REMS-certified healthcare facility for signs or symptoms of CRS and monitor patients for signs or symptoms of CRS for at least 4 weeks after
8kefrtlmfq7kffh9j8ocf7uwcenpke4huutfl 3bkp31ag4pl06
ABBV
ANIX
BIIB
20 Mar 24
integrate their new acquisitions, the healthcare landscape anticipates groundbreaking advancements in treatment options and patient care. The year 2023
b3kulz xel19abez9awk2vo
BMY
TSVT
15 Mar 24
.
Monitor patients at least daily for 7 days following ABECMA infusion at the REMS-certified healthcare facility for signs or symptoms
02td5sq4shbjf33wy8x2haysdfpfoi14bqvjz yagnd7459
BMY
14 Mar 24
patients daily for at least 7 days following BREYANZI infusion at a REMS-certified healthcare facility for signs and symptoms of CRS and neurologic